- Home
- IGMS vs LODE Comparison
IGMS vs LODE Comparison
Compare IGMS & LODE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- LODE
- Stock Information
- Founded
- IGMS 1993
- LODE 2008
- Country
- IGMS United States
- LODE United States
- Employees
- IGMS N/A
- LODE N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- LODE Major Chemicals
- Sector
- IGMS Health Care
- LODE Industrials
- Exchange
- IGMS Nasdaq
- LODE Nasdaq
- Market Cap
- IGMS 82.1M
- LODE 79.6M
- IPO Year
- IGMS 2019
- LODE N/A
- Fundamental
- Price
- IGMS $1.38
- LODE $0.29
- Analyst Decision
- IGMS Hold
- LODE Buy
- Analyst Count
- IGMS 8
- LODE 1
- Target Price
- IGMS $6.14
- LODE $2.60
- AVG Volume (30 Days)
- IGMS 368.0K
- LODE 5.8M
- Earning Date
- IGMS 03-06-2025
- LODE 03-03-2025
- Dividend Yield
- IGMS N/A
- LODE N/A
- EPS Growth
- IGMS N/A
- LODE N/A
- EPS
- IGMS N/A
- LODE N/A
- Revenue
- IGMS $2,918,000.00
- LODE $1,864,811.00
- Revenue This Year
- IGMS $26.85
- LODE $69.41
- Revenue Next Year
- IGMS $125.17
- LODE $56.83
- P/E Ratio
- IGMS N/A
- LODE N/A
- Revenue Growth
- IGMS 57.64
- LODE 117.46
- 52 Week Low
- IGMS $1.26
- LODE $0.13
- 52 Week High
- IGMS $22.50
- LODE $1.01
- Technical
- Relative Strength Index (RSI)
- IGMS 26.21
- LODE 35.36
- Support Level
- IGMS $1.26
- LODE $0.28
- Resistance Level
- IGMS $1.54
- LODE $0.41
- Average True Range (ATR)
- IGMS 0.13
- LODE 0.03
- MACD
- IGMS 0.22
- LODE -0.01
- Stochastic Oscillator
- IGMS 29.27
- LODE 4.85
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About LODE Comstock Inc.
Comstock Inc is engaged in technologies that efficiently use wasted and under-utilized natural resources to produce renewable energy and other products that contribute to balancing uses and emissions of carbon and enhance mineral and material discoveries. The segments of the company are Fuels Metals, Mining, Strategic Investments, and Corporate. The company derives maximum revenue from Strategic Investments segment. The Strategic Investments Segment includes minority equity investments in Quantum Generative Materials LLC (physics-based artificial intelligence), Green Li-ion Pte Limited (lithium-ion battery recycling and cathode production), Sierra Springs Opportunity Fund (strategic direct investment in northern Nevada real estate), and other equity or equity-linked investments.